Exploring Next Generation Probiotics for Metabolic and Microbiota Dysbiosis Linked to Xenobiotic Exposure: Holistic Approach
Metadatos
Afficher la notice complèteAuteur
Torres Sánchez, Alfonso; Ruiz Rodríguez, Alicia; Ortiz Sandoval, Pilar; Moreno, María Alejandra; Ampatzoglou, Antonios; Gruszecka-Kosowska, Agnieszka Malgorzata; Monteoliva Sánchez, Mercedes; Aguilera Gómez, MargaritaEditorial
MDPI
Materia
Microbiota Disrupting Chemicals (MDCs) Microbiota Metabolites Next Generation Probiotics (NGPs) Xenobiotics
Date
2022-10-26Referencia bibliográfica
Torres-Sánchez, A... [et al.]. Exploring Next Generation Probiotics for Metabolic and Microbiota Dysbiosis Linked to Xenobiotic Exposure: Holistic Approach. Int. J. Mol. Sci. 2022, 23, 12917. [https://doi.org/10.3390/ijms232112917]
Patrocinador
FEDER Project Infrastructure IE_2019-198; Instituto de Salud Carlos III; European Commission PI20/01278; FIBAO EU-FORA Programme (2020/2021)Résumé
Variation of gut microbiota in metabolic diseases seems to be related to dysbiosis induced
by exposure to multiple substances called Microbiota Disrupting Chemicals (MDCs), which are
present as environmental and dietary contaminants. Some recent studies have focused on elucidating
the alterations of gut microbiota taxa and their metabolites as a consequence of xenobiotic exposures
to find possible key targets involved in the severity of the host disease triggered. Compilation of data
supporting the triad of xenobiotic-microbiota-metabolic diseases would subsequently allow such
health misbalances to be prevented or treated by identifying beneficial microbe taxa that could be
Next Generation Probiotics (NGPs) with metabolic enzymes for MDC neutralisation and mitigation
strategies. In this review, we aim to compile the available information and reports focused on
variations of the main gut microbiota taxa in metabolic diseases associated with xenobiotic exposure
and related microbial metabolite profiles impacting the host health status. We performed an extensive
literature search using SCOPUS, Web of Science, and PubMed databases. The data retrieval and
thorough analyses highlight the need for more combined metagenomic and metabolomic studies
revealing signatures for xenobiotics and triggered metabolic diseases. Moreover, metabolome and
microbiome compositional taxa analyses allow further exploration of how to target beneficial NGP
candidates according to their alleged variability abundance and potential therapeutic significance.
Furthermore, this holistic approach has identified limitations and the need of future directions to
expand and integrate key knowledge to design appropriate clinical and interventional studies with
NGPs. Apart from human health, the beneficial microbes and metabolites identified could also be
proposed for various applications under One Health, such as probiotics for animals, plants and
environmental bioremediation.